By Hendra Lukman 
A groundbreaking advancement in stem cell transplantation, pioneered at Stanford Medicine, is poised to transform treatment protocols for patients with rare genetic disorders. A novel antibody therapy has demonstrated the ability to prepare patients for life-saving stem cell transplants without the necessity of debilitating chemotherapy or radiation, according to the promising results of a Phase 1 clinical trial. This innovative approach, initially focused on children with Fanconi anemia, a severe inherited condition that renders conventional transplants exceptionally perilous, holds significant promise for broader application across a spectrum of inherited diseases requiring transplantation.
A Paradigm Shift in Transplant Preparation
The core of this breakthrough lies in the development of an antibody therapy that targets and eliminates a patient’s own blood-forming stem cells, a critical step prior to transplant. Traditionally, this ablative conditioning has relied on potent and often toxic agents like radiation and genotoxic chemotherapy, such as busulfan. These treatments, while effective in clearing the way for donor cells, carry substantial risks, including secondary cancers, infertility, and organ damage. The Stanford team’s innovative regimen successfully bypasses these toxicities, offering a safer and more tolerable pathway to engraftment.
Dr. Agnieszka Czechowicz, MD, PhD, assistant professor of pediatrics and co-senior author of the study, expressed enthusiasm for the results. "We were able to treat these really fragile patients with a new, innovative regimen that allowed us to reduce the toxicity of the stem cell transplant protocol," she stated. "Specifically, we could eliminate the use of radiation and genotoxic chemotherapy called busulfan, with exceptional outcomes." The findings, published in the prestigious journal Nature Medicine, detail how the antibody, in conjunction with other supportive medications, enabled successful transplants for three young patients diagnosed with Fanconi anemia. These children have now been monitored for two years post-transplant and continue to exhibit robust health and successful engraftment.
Addressing the Critical Need for Safer Transplants
Fanconi anemia is a particularly challenging condition for transplantation due to its inherent impact on DNA repair mechanisms, which also makes patients highly susceptible to the damaging effects of radiation and chemotherapy. In untreated Fanconi anemia, the bone marrow progressively fails to produce essential blood cells, leading to life-threatening complications such as severe bleeding and recurrent infections. Dr. Rajni Agarwal, MD, professor of pediatric stem cell transplantation and co-first author of the study, underscored the urgency and impact of this new therapy: "If they don’t get a transplant in time, Fanconi anemia patients’ bodies eventually will not make blood, so they die of bleeding or infections. The reason I am so excited about this trial is that it is a novel approach to help these patients, who are very vulnerable."
The antibody used in the trial, known as briquilimab, specifically targets CD117, a protein abundantly present on the surface of hematopoietic stem cells. By binding to this receptor, briquilimab effectively flags these cells for removal by the patient’s own immune system, a process that clears the bone marrow without the widespread collateral damage associated with traditional conditioning agents. This research builds upon decades of dedicated investigation at Stanford Medicine, aiming to demystify and enhance the safety and accessibility of stem cell transplantation.
A Legacy of Innovation: From Bench to Bedside
The genesis of this antibody-based approach can be traced back to early 2000s research conducted by Dr. Czechowicz under the mentorship of Dr. Irving Weissman, MD, a pioneer in stem cell biology and former director of Stanford’s Institute for Stem Cell Biology and Regenerative Medicine. Their foundational studies in animal models demonstrated that blocking the CD117 receptor with antibodies could effectively eliminate stem cells without resorting to radiation or chemotherapy. Through meticulous refinement and collaboration with other Stanford scientists, a human-compatible version of the antibody was identified, paving the way for the clinical trials that have now yielded such encouraging results.
Overcoming Donor Mismatch Challenges
Beyond revolutionizing the conditioning regimen, the Stanford team also addressed another significant barrier to stem cell transplantation: the scarcity of perfectly matched donors. Historically, the inability to find a compatible donor has prevented a substantial percentage of patients, estimated to be up to 40%, from receiving potentially curative transplants. To mitigate this, the researchers implemented a refined approach to donor bone marrow preparation. This involved enriching the donated marrow for CD34+ cells, the crucial blood-forming stem cells, while simultaneously depleting immune cells known as alpha/beta T-cells. The removal of these cells is critical to preventing graft-versus-host disease (GVHD), a dangerous complication where the donor’s immune system attacks the recipient’s body. This innovative method, spearheaded by Dr. Alice Bertaina, MD, PhD, allows for safe and effective transplantation even from half-matched donors, including parents, thereby dramatically expanding the pool of eligible donors.
"We are expanding the donors for stem cell transplantation in a major way, so every patient who needs a transplant can get one," Dr. Agarwal affirmed, highlighting the profound implications for patient access to this life-saving therapy.
Ryder’s Story: A Testament to Hope and Recovery
The transformative potential of this new therapy is vividly illustrated by the experience of Ryder Baker, an 11-year-old boy from Seguin, Texas, who was the first recipient of the antibody-conditioned transplant at Lucile Packard Children’s Hospital Stanford in early 2022. Prior to the transplant, Ryder’s Fanconi anemia significantly impacted his energy levels and overall well-being, leaving him perpetually fatigued and vulnerable to illness. His mother, Andrea Reiley, described the stark contrast in his health: "He was so tired, he didn’t have stamina. It’s completely different now." She added that the condition no longer impedes his active lifestyle. Today, Ryder is a vibrant child, recently completing fifth grade, participating in sports, and even earning an "Up and Coming Player" award for his school soccer team. His remarkable recovery serves as a powerful testament to the efficacy and gentler nature of the new treatment protocol.
Expanding the Horizons of Stem Cell Therapy
The success with Ryder and the other two initial trial participants fuels the researchers’ optimism for extending this life-changing treatment to a broader patient population. While stem cell transplants are most commonly employed for blood cancers, the improved safety profile of this new conditioning method opens doors for its application in a wider array of diseases. "Bone marrow or stem cell transplants are most commonly used in blood cancers, in which the bone marrow is full of malignant cells and patients have no other options," Dr. Czechowicz explained. "But as we’re making these transplants better and safer, we can expand them to more patients including those with many different diseases."
Understanding the Nuances of Fanconi Anemia
Fanconi anemia is a complex genetic disorder characterized by a fundamental defect in DNA repair pathways. This deficiency impairs the bone marrow’s ability to produce adequate numbers of red blood cells, white blood cells, and platelets. Consequently, children with Fanconi anemia often exhibit symptoms such as chronic fatigue, stunted growth, increased susceptibility to infections, and a tendency towards bruising or bleeding. A critical hallmark of the disease is progressive bone marrow failure, which typically emerges by adolescence and is fatal if left untreated. The inherent challenge has been that while stem cell transplantation offers a cure, the conventional preparatory treatments—chemotherapy and radiation—carry a significant risk of inducing secondary cancers later in life, with nearly 80% of patients developing such cancers by age 40. The Stanford team’s antibody-based approach aims to drastically reduce this long-term oncogenic risk.
Early Clinical Successes: A Foundation for the Future
The initial Phase 1 trial involved three children, all under the age of 10, each with distinct genetic variations of Fanconi anemia. Each participant received a single intravenous dose of briquilimab 12 days prior to their transplant. They were subsequently given standard immune-suppressing medications but crucially, no busulfan or radiation. The stem cells for transplantation were sourced from a parent and meticulously processed to remove potentially harmful immune cells. Within a fortnight, the donor stem cells had successfully integrated into the patients’ bone marrow. Notably, none of the children experienced graft rejection. By one month post-transplant, donor cells had almost completely replaced their original bone marrow cells. The research team’s initial target for donor cell presence was a modest 1%, making the achievement of nearly 100% donor cell chimerism within two years an exceptionally positive outcome. "We’ve been surprised by how well it’s worked," Dr. Czechowicz remarked. "We were optimistic that we would get here, but you never know when you’re trying a new regimen."
Life Beyond Transplant: A New Beginning
Despite the significantly reduced toxicity, stem cell transplantation remains a demanding medical intervention. Ryder, for instance, spent over a month in the hospital and experienced temporary side effects such as exhaustion, nausea, and hair loss. His mother recounted the emotional toll: "It was heartbreaking to see him go through things like that — I’d rather go through it than my child. I felt the heartbreak for him, and now he doesn’t have to." Since his recovery, Ryder has experienced a dramatic improvement in his health, marked by physical growth and an end to the constant cycle of illness that previously plagued him. "It used to be huge hits when he would get sick at all, and I really don’t have to worry about that anymore," Ms. Reiley shared, expressing profound relief. She also instills in Ryder a sense of pride, knowing that his pioneering role in this trial will directly benefit future patients.
Charting the Course Forward: Next Steps and Broader Implications
After more than three decades of relying on conventional, albeit toxic, conditioning methods, Dr. Agarwal expressed her profound satisfaction in offering families a demonstrably safer alternative. "When I counsel families, their eyes start to shine as they think, ‘OK, we can avoid the radiation and chemo toxicity’," she observed. The Stanford team is currently spearheading a Phase 2 clinical trial enrolling more children with Fanconi anemia. Furthermore, they are actively investigating the applicability of this antibody-based conditioning for patients with other rare bone marrow failure syndromes, such as Diamond-Blackfan anemia.
While the current antibody approach may not entirely replace chemotherapy or radiation for all cancer patients, particularly those with high burdens of malignant cells, the researchers are exploring its potential to benefit elderly cancer patients who may not tolerate the intensity of traditional conditioning regimens. "That population is often at a disadvantage," Dr. Agarwal noted. "It may provide us with a way to treat them with less intensity so it’s possible for them to get a transplant." The team is also committed to developing next-generation antibody-based therapies to further refine and enhance outcomes for Fanconi anemia and similar conditions.
A Collaborative Endeavor
This pioneering research was a testament to extensive collaboration, involving key contributors such as Dr. Czechowicz, Dr. Agarwal, Dr. Bertaina, and co-senior author Matthew Porteus, MD, PhD. Additional expertise and support were provided by researchers from the University of California, San Francisco; Kaiser Permanente Bernard J. Tyson School of Medicine; St. Jude Children’s Research Hospital; Memorial Sloan Kettering Cancer Center; and Jasper Therapeutics Inc. The study received crucial funding from anonymous donors, the California Institute of Regenerative Medicine, and the Fanconi Cancer Foundation. Jasper Therapeutics generously provided the investigational antibody, briquilimab, and the Stanford Clinical Trial Program played an instrumental role in facilitating the study’s implementation. This multifaceted approach underscores the scientific community’s commitment to advancing patient care through innovation and shared expertise.
